Iworima, Diepiriye G.
Baker, Robert K.
Ellis, Cara
Sherwood, Chris
Zhan, Lisa
Rezania, Alireza
Piret, James M.
Kieffer, Timothy J.
Funding for this research was provided by:
Juvenile Diabetes Research Foundation Canada
Stem Cell Network
Natural Science and Engineering Research Council
Canadian Federation of University Women
Canadian Institutes of Health Research
STEMCELL Technologies
Article History
Received: 26 April 2023
Accepted: 16 November 2023
First Online: 2 January 2024
Declarations
:
: This was not a clinical trial, so consent to participate was not applicable, nor the declaration of Helsinki for ethical principles for medical research involving human subjects. Experiments using human pluripotent stem cells were approved by the University of British Columbia Clinical Research Ethics Board and the Canadian Stem Cell Oversight Committee, title “In vitro differentiation of human embryonic stem cells into functional beta cells.” The use of donor human islets was approved by 1) the University of Alberta, title “Human donor islet procurement for research purposes,” renewed on July 2023, 2) the University of British Columbia, title “ Human materials, nonclinical studies (hESC, hiPSC, human pancreatic islets, human blood samples),” renewed on August 2021.
: Not applicable.
: During part of this work, TJK was serving as Chief Scientific Officer at ViaCyte, Inc., a private biotechnology company developing a stem cell-based therapy for diabetes. The remaining authors declare no competing interests.